Pharming Group (NASDAQ:PHAR) Issues Quarterly Earnings Results

Pharming Group (NASDAQ:PHAR) issued its quarterly earnings results on Thursday. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.06 by ($0.04), FiscalAI reports. Pharming Group had a return on equity of 3.40% and a net margin of 2.51%.The business had revenue of $90.20 million during the quarter, compared to the consensus estimate of $99.52 million.

Here are the key takeaways from Pharming Group’s conference call:

• 2026 revenue guidance was reduced by $30 million to $375 million–$395 million, reflecting continued competitive pressure on RUCONEST and a 0%–5% expected revenue growth range.
• RUCONEST revenue fell 10% year over year to $72.3 million, but management highlighted resilience in the active patient base, which remained at 93% of prior-year levels, and a recovery in new enrollments to 84 in Q2. The company expects RUCONEST revenue to stabilize and return to growth in the second half of 2026.
• JOENJA revenue grew 40% to $17.9 million, with U.S. revenue up 31% and international revenue up 150%. Growth is expected to be supported by launches in Germany and Japan, further U.S. patient identification, and potential pediatric label expansion.
• Two fully enrolled phase II studies evaluating leniolisib in broader primary immunodeficiencies and CVID are expected to produce results in Q4 2026. Positive data could expand JOENJA’s addressable population substantially—CVID is estimated to be up to 40 times larger than APDS—and support a potential blockbuster franchise.
• Pharming reduced full-year operating expense guidance by $15 million to $315 million–$320 million while continuing more than $40 million of incremental R&D investment. Q2 operating profit remained positive, but operating cash flow was negative $9.7 million and cash and marketable securities declined to $159.5 million.

Pharming Group Stock Performance

PHAR stock traded down $0.67 during midday trading on Friday, hitting $10.08. The stock had a trading volume of 26,888 shares, compared to its average volume of 7,883. Pharming Group has a 52 week low of $9.62 and a 52 week high of $21.34. The company has a current ratio of 2.63, a quick ratio of 2.06 and a debt-to-equity ratio of 0.35. The stock has a 50-day simple moving average of $13.02 and a 200 day simple moving average of $15.19. The firm has a market capitalization of $713.46 million, a price-to-earnings ratio of 84.00 and a beta of -0.04.

Hedge Funds Weigh In On Pharming Group

A number of hedge funds have recently made changes to their positions in the business. EverSource Wealth Advisors LLC bought a new position in shares of Pharming Group during the 2nd quarter worth about $32,000. SmartHarvest Portfolios LLC bought a new stake in Pharming Group in the fourth quarter valued at about $224,000. Millennium Management LLC acquired a new position in Pharming Group in the fourth quarter worth about $360,000. Finally, NewEdge Advisors LLC raised its position in Pharming Group by 11,310.3% in the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock worth $510,000 after purchasing an additional 28,615 shares in the last quarter. Institutional investors and hedge funds own 0.03% of the company’s stock.

Trending Headlines about Pharming Group

Here are the key news stories impacting Pharming Group this week:

• Positive Sentiment: Joenja momentum remains a key growth driver. Management highlighted continued commercial momentum for Joenja and expects upcoming clinical data to support potential expansion into broader therapeutic uses. Pharming reports second quarter and first half 2026 financial results
• Positive Sentiment: Near-term clinical catalysts could broaden the company’s addressable market. The earnings presentation and conference call pointed to forthcoming clinical readouts that may provide additional support for Joenja’s development and commercial opportunity. Pharming Group Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Management maintained a substantial full-year revenue outlook. Pharming now expects 2026 revenue of approximately $375 million to $395 million, leaving room for continued growth but below the roughly $403.1 million analyst consensus. Pharming Group 2026 Q2 Results Earnings Call Presentation
• Negative Sentiment: Second-quarter results missed consensus estimates. Pharming reported EPS of $0.02 versus expectations of $0.06 and revenue of $90.2 million versus the $99.52 million consensus, raising concerns about near-term sales execution and profitability.
• Negative Sentiment: The company reduced its 2026 revenue guidance by about $30 million. Weaker sales led Pharming to lower its outlook, a significant negative revision that is likely the primary reason the stock has declined. Pharming lowers 2026 revenue guidance

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Oppenheimer reaffirmed an “outperform” rating on shares of Pharming Group in a research report on Thursday. Wall Street Zen downgraded shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Canaccord Genuity Group initiated coverage on shares of Pharming Group in a research report on Friday, April 10th. They issued a “buy” rating and a $37.00 price target on the stock. Weiss Ratings downgraded shares of Pharming Group from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, May 11th. Finally, Zacks Research raised shares of Pharming Group from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $38.33.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.